Operating
Divestiture Gains And Royalties
Bristol-Myers Squibb Divestiture Gains And Royalties decreased by 88.4% to $34.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 88.4%, from $292.00M to $34.00M. Over 3 years (FY 2021 to FY 2024), Divestiture Gains And Royalties shows an upward trend with a 17.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryCapital Allocation
SignalHigher is better
VolatilityVolatile
First reportedQ1 2020
Last reportedQ1 2026Apr 30, 2026
How to read this metric
Higher values indicate successful asset optimization or strong intellectual property licensing performance.
Detailed definition
This captures cash inflows or accounting adjustments related to the sale of business units, product lines, or ongoing ro...
Peer comparison
Frequent in large pharma companies that regularly prune portfolios and license out secondary assets.
Metric ID:
operating_divestiture_gains_and_royaltiesHistorical Data
17 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $171.00M | $171.00M | $171.00M | $265.75M | $265.75M | $265.75M | $265.75M | $221.00M | $221.00M | $221.00M | $221.00M | $279.75M | $279.75M | $279.75M | $279.75M | $292.00M | $34.00M |
| QoQ Change | — | +0.0% | +0.0% | +55.4% | +0.0% | +0.0% | +0.0% | -16.8% | +0.0% | +0.0% | +0.0% | +26.6% | +0.0% | +0.0% | +0.0% | +4.4% | -88.4% |
| YoY Change | — | — | — | — | +55.4% | +55.4% | +55.4% | -16.8% | -16.8% | -16.8% | -16.8% | +26.6% | +26.6% | +26.6% | +26.6% | +4.4% | -88.4% |
Range$34.00M – $292.00M
CAGR-33.2%
Avg YoY Growth+9.3%
Median YoY Growth+26.6%
Divestiture Gains And Royalties at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's divestiture gains and royalties?
- Bristol-Myers Squibb (BMY) reported divestiture gains and royalties of $34.00M in Q1 2026.
- How has Bristol-Myers Squibb's divestiture gains and royalties changed year-over-year?
- Bristol-Myers Squibb's divestiture gains and royalties decreased by 88.4% year-over-year, from $292.00M to $34.00M.
- What is the long-term trend for Bristol-Myers Squibb's divestiture gains and royalties?
- Over 3 years (2021 to 2024), Bristol-Myers Squibb's divestiture gains and royalties has grown at a 17.8% compound annual growth rate (CAGR), from $684.00M to $1.12B.
- What does divestiture gains and royalties mean?
- Income derived from selling business assets or collecting royalties.